GlassScriptPhysician profile
Darren Pham
NPI 1235779885
$2,850.46
in general payments reported to CMS, 2019-2025
15 companies · $24.34 in 2025
The $24.34 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $92.82 · 2021: $904 · 2022: $1,100 · 2023: $298 · 2024: $432 · 2025: $24.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $754.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $542.02 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $398.04 | 2021-2023 | Cequa |
| Biotissue Holdings INC. | $321.64 | 2021-2024 | |
| Aerie Pharmaceuticals, INC. | $299.34 | 2020-2021 | |
| Abbvie INC. | $241.41 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $224.32 | 2023-2024 | Infuse, Xiidra, Miebo |
| Alcon Vision LLC | $217.71 | 2021-2024 | Total30, Argos |
| Johnson & Johnson Surgical Vision, INC. | $192.52 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $167.19 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $116.51 | 2021 | |
| Allergan, INC. | $32.97 | 2021-2022 | |
| Coopervision INC. | $32.56 | 2024 | Myday Contact Lens |
| Optos, INC. | $24.15 | 2021 | |
| Oyster Point Pharma, INC. | $23.23 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.85 | 2023 | Tobradex St |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darren Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.